STAMFORD, Conn.—Johnson & Johnson (NYSE: JNJ) recently announced that it has closed a transaction to co-lead the Series A funding of TECLens, a refractive technology start-up that is developing a novel, non-incisional refractive correction procedure that leverages a technique known as corneal cross-linking (CXL) to reshape the cornea. According to J&J, this investment in the early-stage start-up furthers a commitment to innovation in ophthalmology and broadening its portfolio of refractive technologies. “As a company dedicated to making vision possible for more than 40 million people every year, fostering early innovation, partnering with experts, and leveraging new technology is how we’ll continue to improve outcomes for patients,” said Peter Menziuso, company group chairman, Vision, J&J.

TECLens utilizes a non-invasive treatment by incorporating quantitative corneal crosslinking (qCXL) technology and a CXLens device, the company noted. This new technology currently in clinical development means potential relief for a wider range of patients, including those who are not good candidates for other refractive solutions or those who are looking for alternative solutions to traditional refractive surgeries.

“This is an important and exciting partnership of our groundbreaking technology and J&J’s decades of leadership in eye health," said Tom Dunlap, CEO of TECLens. "Together with J&J and our financing partners, we will be able to make a significant positive impact on non-invasive vision correction for so many individuals.”

The company noted that the transaction was closed by Johnson & Johnson Innovation (JJDC Inc.), the strategic venture capital arm of Johnson & Johnson, and that the CXLens device is not approved by health authorities. TECLens has successfully tested the device in keratoconus patients and is currently planning the first refractive correction clinical studies, according to the announcement.